This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page | Contact Us | Sign In | Register
News & Press: Impact Statements

Impact Statement MHRA – New Rules from January 2021

09 October 2020   (0 Comments)
Posted by: Tamsin Marshall
Share |

The UK has left the EU, and the transition period after Brexit comes to an end this year.
From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the UK’s standalone medicines and medical devices regulator.


Transition from the EU allows the UK to offer fully independent regulatory decisions for both devices and pharmaceuticals, both nationally and in joint work with other international regulators.


Stakeholders need to get ready for new rules from 1 January 2021.


The MHRA has published details of what you what you'll need to do from 1 January 2021. The information will be updated if anything changes.


Click on the following link to see the detailed MHRA notifications:-New Rules for 2021


You can also check what else you need to do during the transition period.


Readers may also be interested to see comment on the changes from The Association of British Pharmaceutical Industries (ABPI) ABPI response statement

 

Download this document


Prepared by Malcolm Holmes C.Chem MRSC

 

Please feel free to share this article via the share button above. 



Contact

6a Kingsdown Orchard, Hyde Road Swindon, Wiltshire SN2 7RR UK

tel: +44 (0) 1793 824254 email: info@phss.co.uk

Connect